Author

E. Nasajpour

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

C. K. Petritsch· 2 shared D. Hambardzumyan· 2 shared G. A. Grant· 2 shared L. M. Prolo· 2 shared A. Beck· 1 shared A. Comba· 1 shared A. J. Nicola Candia· 1 shared A. M. Sonabend· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. K. Petritsch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas

M. B. Garcia Fabiani, S. Haase, K. Banerjee, Z. Zhu, B. McClellan, A. Mujeeb, Y. Li, C. E. Tronrud, M. L. Varela, M. E. J. West, J. Yu, P. Kadiyala, A. Taher, F. J. NUNEZ, M. S. Alghamri, , Sart

This study shows that H3.3-G34R mutations reprogram the tumor immune microenvironment in diffuse hemispheric gliomas, enhancing the efficacy of immune stimulatory gene therapy and leading to long-term survival in treated mice.

bioRxiv · Jun 13, 2023 · PreprintCancer Biology

BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune CheckpointSensitivity in BRAFV600E-mutant Glioma

Y. L. Xing, D. Panovska, J.-W. Park, S. Grossauer, K. Koeck, B. Bui, E. Nasajpour, J. J. Nirschl, Z.-P. Feng, P. Cheung, P. Habib, R. Wei, J. Wang, W. Thomason, J. Xiu, , C. K. Petritsch

This study shows that BRAF/MEK inhibition induces cell state transitions in BRAFV600E-mutant gliomas, leading to PD-L1 upregulation and immune evasion, which can be overcome by combining with immune checkpoint inhibition.

bioRxiv · Feb 3, 2023Cancer Biology